Search
Search
Liquid biopsy enables non-invasive biomarker testing to identify and track oncogenic mutations. It can detect and monitor cancer through the analysis of circulating tumor DNA (ctDNA) and other biomarkers found in blood or other bodily fluids. Digital PCR (dPCR) can enhance liquid biopsy research by providing highly sensitive and precise quantification of DNA and RNA molecules, enabling the detection of low-abundance genetic mutations and variations, the tracking of tumor dynamics, and assessment of minimal residual disease.
Characterizing ctDNA helps researchers detect cancer early, measure therapeutic response, quantify residual tumor burden, and monitor emerging resistance to potential therapies. Because ctDNA fragments are typically short and very low in concentration, the sensitivity of dPCR makes it an ideal tool for ctDNA studies.
Absolute Q Liquid Biopsy dPCR assays enable reproducible, specific detection of known somatic mutations. Each predesigned assay has been validated using controls to detect down to 0.1% variant allele frequency in genes relevant for cancer research.
Absolute Q Liquid Biopsy dPCR assays are:
To order Absolute Q Liquid Biopsy dPCR Assays, indicate the desired quantity in the appropriate assay row, then scroll to the bottom of the table and click 'Add to cart'. Follow the in-cart instructions to complete your purchase.
For Research Use Only. Not for use in diagnostic procedures.